Research programme: autologous cytokine-induced killer cell therapy - Chuan An Biotechnology

Drug Profile

Research programme: autologous cytokine-induced killer cell therapy - Chuan An Biotechnology

Latest Information Update: 26 Apr 2017

Price : $50

At a glance

  • Originator Chuan An Biotechnology
  • Class Antineoplastics; Cell therapies
  • Mechanism of Action Cytokine-induced killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hepatocellular carcinoma

Most Recent Events

  • 26 Apr 2017 Preclinical trials in Hepatocellular carcinoma in China (Parenteral)
  • 26 Apr 2017 Chuan An Biotechnology plans a phase I/II trial for Hepatocellular carcinoma in China (NCT03124498)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top